The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
出版年份 2020 全文链接
标题
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
作者
关键词
-
出版物
Frontiers in Neurology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-03-06
DOI
10.3389/fneur.2020.00149
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease
- (2019) Daan L.K. de Jong et al. HYPERTENSION
- Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
- (2019) Sebastian Palmqvist et al. EMBO Molecular Medicine
- Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years
- (2018) Suzanne E. Schindler et al. Alzheimers & Dementia
- Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
- (2018) Lawrence S. Honig et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Renin-Angiotensin System and Antihypertensive Drugs in Alzheimer's Disease: Current Standing of the Angiotensin Hypothesis?
- (2018) Patrick G. Kehoe et al. JOURNAL OF ALZHEIMERS DISEASE
- Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
- (2018) Brian Lawlor et al. PLOS MEDICINE
- Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI
- (2018) Alexander Morin et al. Frontiers in Aging Neuroscience
- The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
- (2017) Ellis Niemantsverdriet et al. JOURNAL OF ALZHEIMERS DISEASE
- Statistical properties of continuous composite scales and implications for drug development
- (2017) Hong Liu-Seifert et al. Journal of Biopharmaceutical Statistics
- 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
- (2017) Hilkka Soininen et al. LANCET NEUROLOGY
- Blood-based NfL
- (2017) Oskar Hansson et al. NEUROLOGY
- Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
- (2017) Piotr Lewczuk et al. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Widespread tau seeding activity at early Braak stages
- (2016) Jennifer L. Furman et al. ACTA NEUROPATHOLOGICA
- Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials
- (2016) Jeff Sevigny et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
- (2016) Bryan D. James et al. BRAIN
- Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
- (2016) Niklas Mattsson et al. EMBO Molecular Medicine
- ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
- (2016) Jinping Wang et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum
- (2016) Alberto Serrano-Pozo et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow
- (2016) Olga Meulenbroek et al. BMJ Open
- New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials
- (2015) Nishant Verma et al. Alzheimers Research & Therapy
- Introducing a new tool for optimizing responsiveness to decline in early Alzheimer's disease
- (2014) Suzanne Hendrix et al. Alzheimers & Dementia
- The Spleen Tyrosine Kinase (Syk) Regulates Alzheimer Amyloid-β Production and Tau Hyperphosphorylation
- (2014) Daniel Paris et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
- (2014) Brian Lawlor et al. BMJ Open
- Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series
- (2013) Gabor G. Kovacs et al. ACTA NEUROPATHOLOGICA
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
- (2013) A. P. Sagare et al. Cold Spring Harbor Perspectives in Medicine
- Working memory task performance and chunking in early Alzheimer's disease
- (2011) Jonathan Huntley et al. BRITISH JOURNAL OF PSYCHIATRY
- Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier
- (2011) Corbin Bachmeier et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Unknown
- (2011) Daniel Paris et al. MOLECULAR MEDICINE
- Clinical Trial Design Issues in Mild to Moderate Alzheimer Disease
- (2008) David S. Knopman Cognitive and Behavioral Neurology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More